Tandem Diabetes Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tandem Diabetes Care reports robust sales growth and strategic innovations

Tandem Diabetes Care's strong financial performance, innovative product portfolio, and global market expansion efforts position it for continued growth and competitiveness.
While facing short-term challenges like seasonal EBITDA fluctuations and acquisition-related headwinds, Tandem's strategic focus on new product launches and market awareness presents opportunities for long-term success.
The company's emphasis on technology advancements, clinical initiatives, and leadership continuity underscores its commitment to driving innovation and meeting customer needs in the insulin therapy market.
With a clear roadmap for 2023, including revenue projections, margin expectations, and product development plans, Tandem is poised to navigate challenges and capitalize on growth opportunities in the evolving healthcare landscape.

Tandem Diabetes Care reports strong Q1 performance amidst competitive challenges

Tandem Diabetes Care's Q1 2023 earnings call showcased strong performance driven by product success and customer loyalty, despite challenges in international revenue and competitive landscape noise.
The company's focus on innovation, cost management, and product enhancements positions it well for long-term growth and market expansion, with opportunities in Libre integration and upcoming product launches.
While facing short-term challenges in Q2 revenue and margins, Tandem Diabetes Care remains confident in achieving its objectives through prudent cost management and commitment to product excellence.

Tandem Diabetes Care exceeds Q2 targets, eyes sustainable growth

Tandem Diabetes Care (TNDM) showcased strong Q2 performance, with a focus on sustainable growth and profitability. While facing challenges like market uncertainties, the company is leveraging opportunities through new product launches and cost efficiencies for future growth.

Tandem Diabetes Care surpasses Q3 sales expectations amidst market challenges

Tandem Diabetes Care's Q3 performance exceeded expectations with strong sales and positive margins, despite challenges in OUS distribution.
The company's focus on innovation, product success, and market positioning sets the stage for future growth opportunities.
Navigating disruptions and seizing growth potential through new product launches and market expansion are key priorities for Tandem.
Overall, Tandem remains optimistic about its trajectory and is actively pursuing strategic opportunities for growth.

Tandem Diabetes Care reports strong sales growth and strategic focus

Tandem Diabetes Care's Q4 2023 Earnings Call highlighted strong sales performance, positive customer feedback, and strategic focus on new product launches and operational efficiencies.
While facing challenges from unique events and increasing competition, Tandem is leveraging opportunities in U.S. and international markets, focusing on growth and innovation.
The company's outlook for 2024 includes a robust sales guidance, expansion plans, and a strategic approach to address market challenges and capitalize on emerging opportunities.

Tandem Diabetes Care reports robust Q1 sales growth and international expansion

Tandem Diabetes Care's Q1 2024 earnings call highlighted strong sales growth, successful product launches, and innovation in AID systems, with a focus on maintaining pricing and expanding internationally.
Challenges include pricing strategies, monitoring Mobi's impact, and navigating competitive OUS markets, while opportunities lie in market expansion, health outcome studies validation, and improving access and affordability.
Overall, Tandem's performance reflects a strategic approach to growth through product innovation, market expansion, and a focus on enhancing access and affordability in the diabetes care market.

Tandem Diabetes Care (TNDM) posts strong Q2 results, raises 2024 guidance

Tandem Diabetes Care (TNDM) reported robust Q2 2024 performance with sales growth, improved gross margin, and raised sales guidance. The company's focus on new products and commercial excellence positions it well for future growth.

Tandem Diabetes Care achieves record sales and positive cash flow

Tandem Diabetes Care delivered a strong performance in Q3 2024, marked by record sales and positive free cash flow. The company's focus on innovation, market awareness, and customer retention are key strengths. While facing challenges in a competitive market, Tandem Diabetes Care is well-positioned to capitalize on growth opportunities in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.

Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.

Here's Why You Should Hold on to Tandem Diabetes Stock for Now

Bristol-Myers

Neurocrine Biosciences

QuidelOrtho Corp

Teladoc

Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.

Teladoc, Bristol Myers, Quidel, Neurocrine Bio, Tandem Diabetes: 5 Health Stocks To Monitor Closely

Eli Lilly

These two diabetes companies have been beating the market all year long, but that’s not the only reason you should consider investing in them.

2 Top Diabetes Stocks to Buy in May

Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.

Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q1 2020 Results - Earnings Call Transcript

Investors might consider the company's products to be essential, but the business could face temporary problems getting products into the hands of new customers.

Will Tandem Diabetes Care Experience a COVID-19 Slowdown?

Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.

Here's Why You Should Add Tandem Diabetes to Your Portfolio

Tandem Diabetes Care: This Is A Coronavirus-Resilient Pick For April 2020

Amazon

These two companies have handled the sell-off better than most, and they could keep on growing long after the COVID-19 outbreak ends.

2 Stocks That Can Carry You Through the Coronavirus Market Crash -- and Beyond

Exact Sciences

58.com

The coronavirus may have temporarily slowed them down, but some businesses are built better than others to shrug off the COVID-19 contagion.

3 High-Growth  Stocks That Could Soar

AeroVironment

Chemed

Costco

FormFactor

This is a good time to go for safe stocks so that in the event of any further market turmoil the stockholders do not lose significantly. Stocks with low debt-to-equity ratio offer that safety.

Buy These 5 Low Leverage Stocks Amid Coronavirus-Led Sell Off

Tandem Diabetes Care sees its Relative Strength Rating reach the 80-plus level.
The post Stocks Showing Improving Market Leadership: Tandem Diabetes Care Earns 82 RS Rating appeared first on Investor's Business Daily.

Stocks Showing Improving Market Leadership: Tandem Diabetes Care Earns 82 RS Rating

Recent regulatory go-aheads for Tandem Diabetes' (TNDM) insulin pump systems anticipated to boost global pump shipments as well as expand its customer base.

Tandem Diabetes Wins FDA's iAGC Designation for Basal-IQ

The insulin pump manufacturer turned in a solid year of progress in 2019, but full-year 2020 guidance might be at odds with initial Wall Street expectations.

Will Tandem Diabetes Care Keep Its Premium Valuation in 2020?

Despite the unexpected result, the company's stock price sank on the day.

Tandem Diabetes Care Posts Surprise Q4 Profit

Tandem Diabetes (TNDM) once again registers strong domestic pump shipment in Q4.

Tandem Diabetes (TNDM) Q4 Earnings Beat Estimates, Margins Up

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q4 2019 Results - Earnings Call Transcript

Shares of TNDM stock slipped late Monday after the diabetes treatment company unexpectedly posted a fourth-quarter profit, but light sales.

Leading Diabetes Player Unexpectedly Posts A Profit; But Sales Lag

International Money Express Inc.

Kirkland Lake Gold

USANA Health Sciences

Four top-ranked liquid stocks that investors can bank on for fat returns.

4 Best-Ranked Liquid Stocks for Alluring Returns

Tandem Diabetes: Advancing New Innovations Amid Competitor's Woes

DexCom

Insulet

According to The American Diabetes Association, every $1 in $7 spent in healthcare is spent on diabetes or its complications. We look at three companies well-positioned to capture this market.

3 Great Diabetes-Focused Stocks

Tandem Diabetes is poised to outperform bearish quarterly expectations, an analyst said as he predicted Tandem Diabetes stock would continue a sizable run in 2020 and take share from rivals.

Why This Diabetes Stock Could Sprint In 2020 On Medtronic's Setback

Tandem Diabetes Care (TNDM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Should You Buy Tandem Diabetes Care (TNDM) Ahead of Earnings?

The worst performer among these stocks has soared more than 70% over the last 12 months.

Want to Get Rich Investing in Healthcare? Check Out These Diabetes Stocks

Applied Therapeutics Inc

Community Health Systems

Enphase Energy

Fulgent Genetics

Better-than-expected earnings, positive development in the U.S.-China trade relationship, China stimulus measures, easing policies and slew of upbeat economic data buoyed the stocks.

News for Tandem Diabetes Care Stock (TNDM)